Perspective Therapeutics, has come out with a proprietary product for targeted alpha-particle therapy (TAT), VMT-α-NET, which is a modified somatostatin receptor targeted peptide with improved pharmacokinetics and chelation of ²⁰³Pb/²¹²Pb. The VMT chelator efficiently chelates ²¹²Pb as well as its daughter ²¹²Bi. The Company is developing VMT-α-NET for the treatment and diagnosis of somatostatin receptor subtype 2 (SSTR2)-expressing neuroendocrine tumors.

Perspective Therapeutics announced that the first patient was dosed at the University of Iowa in an investigator-initiated Phase 1 trial evaluating the safety of [212Pb]VMT-α-NET, in patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing neuroendocrine tumors (NETs). The patients being enrolled in the study have either progressed or relapsed after previous therapies, including currently approved peptide receptor radionuclide therapies ("PRRT").

The trial is a single-center, open-label study of [²¹²Pb]VMT-α-NET that is designed to explore safety and efficacy when pre-treatment dose planning is aided by imaging with [²⁰³Pb]VMT-α-NET using quantitative SPECT/CT imaging. Participants are assigned a radiation dose to the kidneys that may not be exceeded which is tailored to each person's unique tumor uptake of [203Pb]VMT-α-NET and how long it lasts in the body.

The company also carried out a clinical study at a site in Germany in four neuroendocrine tumor (NET) patients who were administered VMT-α-NET and the first human images were published.

To read more please visit:

Perspective Therapeutics Announced First Patient Dosed in a Phase 1 Study of [(212)Pb]VMT-α-NET to Treat Refractory or Relapsed Neuroendocrine Tumors

Perspective Therapeutics Announced First Ever Human SPECT Imaging of Pb-212 with VMT-α-NET by Clinical Collaborators in Germany

Source: Perspective